reports
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Op...
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives Acquire cell therapy manufacturing facility with clinical and commercial capabilitiesFurther ExacTcell platform for additional clinical trials based on successful completion of POCHighlight full year financial results and clarify key financial items WARREN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virolo...
electroCore to Announce First Quarter March 31, 2024 Financial Results...
electroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024 ROCKAWAY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the first quarter ended March 31, 2024, after the close of the market on Wednesday, May 8, 2024. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Wednesday, May 8, 4:30 PM EDTDomestic: 877-407-8835International: Conferen...
Dalata Hotel Group PLC: TVR-Total Voting Rights
Dalata Hotel Group PLC (DAL,DHG) Dalata Hotel Group PLC: TVR-Total Voting Rights 01-May-2024 / 12:58 GMT/BST Total Voting Rights ISE: DHG LSE: DAL In conformity with Regulation 20 of the Transparency (Directive 2004/109/EC) Regulations 2007, Dalata Hotel Group plc announces that: As of 1 May 2024, Dalata Hotel Group plc’s share capital consists of 224,430,160 Ordinary Shares of nominal value €0.01 each. Dalata Hotel Group plc does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in Dalata Hotel Group plc is 224,430,160. The ...
Radiation-Tolerant PolarFire® SoC FPGAs Offer Low Power, Zero Configur...
Radiation-Tolerant PolarFire® SoC FPGAs Offer Low Power, Zero Configuration Upsets, RISC-V Architecture for Space Applications Along with Microchip’s Mi-V ecosystem, new device family helps system designers to lower power, size and weight and speed time to market CHANDLER, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Developers of spacecraft electronics utilize radiation-tolerant (RT) field programmable gate arrays (FPGAs) to ensure high performance, reliability, power-efficiency and the best-in-class security for emerging space domain threats. To take it a step further and help provide fast...
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership changes, including the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. as interim CEO. Rachelle Jacques will step down as Akari’s Chief Executive Officer effective today. Melissa Bradford-Klug will step down as Akari’s Chief Operating Officer effective today. In connection with Ms. J...
Recursion to Participate in Upcoming Investor Conferences
Recursion to Participate in Upcoming Investor Conferences SALT LAKE CITY, May 01, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Bank of America Securities Healthcare Conference – May 14-16, 202452nd Annual JP Morgan Global Technology Conference – May 20-22, 2024 About Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recur...
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan...
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic diseaseAkari Therapeutics announces leadership changes in separate Akari press release BOSTON and PLEASANTON, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX, “Akari”) and Peak Bio Inc. (OTC: PKBO, “Peak”) today announced completion of a joint portfolio prioritization review pursuant to which the combined entity...
Locafy Reports Fiscal Third Quarter 2024 Results
Locafy Reports Fiscal Third Quarter 2024 Results Company Striving Towards Near-Term Profitability Following Go-to-Market Approach Revamp and Cost Reduction Initiatives New Pay-Per-Click SEO Pricing Model Gaining Strong Traction in Multiple Market Sectors Streamlined Operations Results in Record Quarterly Gross Margin of 83.6% PERTH, Australia, May 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LCFY, LCFYW) (“Locafy” or the “Company”), a globally recognized software-as-a-service technology company specializing in “entity-based” search engine optimization (SEO), today reported financial result...
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree...
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story Busy is getting candid about navigating her ADHD diagnosis and treatment experience with Qelbree®The percentage of women newly diagnosed with ADHD between 23-29 and 30-49 years of age nearly doubled in just two years (2020-2022)1Although symptoms are present in childhood, a significant portion of women with ADHD don’t receive a diagnosis until they are adults2 ROCKVILLE, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Actress, author, podcaster, and mother of two, Busy Philipps is teaming up with Supernus Pharmaceuticals ...
Conduent Reports First Quarter 2024 Financial Results
Conduent Reports First Quarter 2024 Financial Results Key Q1 2024 Highlights Revenue: $921MPre-tax Income: $127MAdj. EBITDA Margin(1): 7.5%New business signings ACV(2): $99MNet ARR Activity Metric(2) (TTM): $17M FLORHAM PARK, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Conduent (NASDAQ: CNDT), a global technology-led business process solutions and services company, today announced its first quarter 2024 financial results. Cliff Skelton, Conduent President and Chief Executive Officer stated, “Q1 2024 is a continued reflection of progress in our portfolio performance overlaid by t...
Carpenter Technology Reports Third Quarter Fiscal Year 2024 Results
Carpenter Technology Reports Third Quarter Fiscal Year 2024 Results Exceeded Third Quarter Operating Income GuidanceIncreasing Fourth Quarter Operating Income OutlookGenerated Positive Free Cash Flow PHILADELPHIA, May 01, 2024 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) (the “Company”) today announced financial results for the fiscal third quarter ended March 31, 2024. For the quarter, the Company reported operating income of $75.9 million, and earnings per diluted share of $0.12. Excluding noncash special items discussed below, adjusted operating income was $90....
HF Foods to Report First Quarter 2024 Results on May 8, 2024
HF Foods to Report First Quarter 2024 Results on May 8, 2024 Pre-Recorded Earnings Call Webcast Will Be Available on Investor Relations Website LAS VEGAS, May 01, 2024 (GLOBE NEWSWIRE) -- HF Foods Group Inc. (NASDAQ: HFFG) (“HF Foods”, or the “Company”), a leading food distributor to Asian restaurants across the United States, today announced it will report financial results for the first quarter ended March 31, 2024, on Wednesday, May 8, 2024, before market open. Prepared remarks from members of the executive management team discussing these results with additional comments and detail...
GoHealth to Present at the RBC Capital Markets Global Healthcare Confe...
GoHealth to Present at the RBC Capital Markets Global Healthcare Conference CHICAGO, May 01, 2024 (GLOBE NEWSWIRE) -- (GoHealth) (NASDAQ: GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced the company will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 2:05 p.m. Eastern Time. A live webcast of the presentation may be accessed through a link that will be posted on GoHealth’s Investor Relations website, . A replay will be available through the same link following the conference. About GoHeal...
Century Aluminum Company Reports First Quarter 2024 Results
Century Aluminum Company Reports First Quarter 2024 Results CHICAGO, May 01, 2024 (GLOBE NEWSWIRE) -- Century Aluminum Company (NASDAQ: CENX) today announced its first quarter 2024 results. Business Highlights Net sales of $489.5 millionRealized LME aluminum price of $2,190/T in first quarter is up $8/T from prior quarterReported net income attributable to Century stockholders of $246.8 million and adjusted EBITDA attributable to Century stockholders of $25.0 million1Cash and cash equivalents of $93.5 million and strong liquidity of $302.0 million as of March 31, 2024Selected by U.S. De...
Abcourt Announces Private Placement Extension and Results of the Speci...
Abcourt Announces Private Placement Extension and Results of the Special Meeting of Shareholders NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES ROUYN-NORANDA, Quebec, May 01, 2024 (GLOBE NEWSWIRE) -- Abcourt Mines Inc. (“Abcourt” or the “Corporation”) (TSX Venture: ABI) is pleased to extend its previously announced non-brokered private placement of up to 100,000,000 Units at a price of $0.05 per Unit for aggregate gross proceeds of up to $5,000,000 (the “Offering”). Each Unit consists of one common share of the Corporation (a “Share”) and on...
CytomX Therapeutics to Report First Quarter 2024 Results and Provide a...
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024 - CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study - - Management to hold conference call at 5 p.m. EDT / 2 p.m. PDT on May 8th- SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report first quarter 2024 results a...
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral An...
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza BOTHELL, Wash., May 01, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces completion of enrollment of 78 subjects who were infected with influenza A in a randomized, double-blind, placebo-controlled Phase 2a human challenge clinical study evaluating the safety, tolerability, antiviral and clinical measurements of its novel, broad-spectrum, oral PB2 inhibitor CC-42344. CC-42344 is a new class of antiviral ...
SPAR Group Completes Acquisition of Minority Interest in Resource Plus
SPAR Group Completes Acquisition of Minority Interest in Resource Plus Acquisition Results in 100% Ownership of U.S. Business AUBURN HILLS, Mich., May 01, 2024 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: SGRP) (“SPAR,” “SPAR Group,” or the “Company”), a provider of merchandising, marketing, and distribution services, announces the acquisition of the remaining minority interest of Resource Plus, a U.S.-based joint venture. “SPAR established the joint venture with Resource Plus in 2017 to open new segments and expand the company’s capabilities. The JV agreement enabled SPAR to accelerate the g...
Prime Medicine to Participate in the 27th Annual Milken Institute Glob...
Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will participate in a panel discussion at the 27th Annual Milken Institute Global Conference entitled “Things That Will Blow Your Mind.” The panel will bring together innovators across multiple discipline...
Catalyst Pharmaceuticals to Participate at the BofA Securities Health ...
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024 CORAL GABLES, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming BofA Securities Health Care Conference 2...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.